These include a biopsy-based immunohistochemistry (IHC) test for expression level for the PD-L1 protein with an overall accuracy of around 40% [4] and tumour burden biopsy-based sequencing markers, with notably poor meta-data accuracy [4,18]. This evidence concerns the gene CD274 and neoplasm.